跳至主要内容
临床试验/NCT05565001
NCT05565001招募中不适用

Structural and Functional Cerebral Changes After Infusion of ATP Sensitive Potassium Channel Opener Levcromakalim.

Danish Headache Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
1
主要终点
Dynamic diffusion weighted image (DWI)

研究概览

简要总结

The aim of the present study to investigate whether

  • Opening of KATP channels causes migraine pain by activation of meningeal nociceptors and ascending trigeminal nociceptive pathways.
  • Opening of KATP channels causes migraine aura by induction of CSD.

详细描述

Migraine Pain The trigeminovascular system is the anatomical and physiological substrate of migraine pain. Nociceptive transmission originates from activation and sensitization of first-order trigeminovascular neurons. Their cell bodies are in the trigeminal ganglion, and their afferent fibers innervate the meninges and its vessels. Ascending nociceptive transmission from the trigeminal ganglion is projected to the brain stem, activating and sensitizing second-order trigeminovascular neurons, including those in the spinal trigeminal nucleus. This, in turn, activates and sensitizes third-order trigeminovascular neurons in the thalamus, which subsequently relay the nociceptive transmission to the somatosensory cortex and other cortical areas, ultimately resulting in migraine pain.

Although the biological underpinnings of migraine pain are incompletely understood, signaling pathways have been identified that are putatively responsible for the genesis of migraine pain. Recent human experimental data have implicated opening of KATP channels in migraine pathogenesis. In two randomized controlled trials, it was demonstrated that intravenous infusion of levcromakalim - an opener of KATP channels - induced migraine pain in people with migraine with and without aura.

  • It remains unknown whether KATP channel opening causes migraine pain by activation of meningeal nociceptors and ascending trigeminal nociceptive pathways, as proposed during spontaneous migraine attacks.

Migraine Aura About one-third of people with migraine experience aura symptoms, which are characterized by reversible focal neurologic symptoms, typically comprising visual or hemisensory disturbances. The physiological substrate of the aura phase of migraine is thought to be cortical spreading depression (CSD), a self-propagating wave of depolarization across the cerebral cortex that disrupts ionic gradients and is followed by cerebral hypoperfusion. Recently, it was reported that intravenous infusion of levcromakalim - an opener of KATP channels - induced migraine aura in migraine with aura patients.

  • It remains unknown whether KATP channel opening causes CSD which leads to migraine aura, as observed during spontaneous migraine attacks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Migraine patients
  • 18-60 years.
  • 50-100 kg.
  • Women of childbearing potential must use adequate contraception.

排除标准

  • A history of serious somatic disease
  • Any other type of headache (except episodic tension-type headache less than once a month) Daily intake of any medication except contraceptives Contraindications for MRI scan.

研究组 & 干预措施

Levcromakalim

Active Comparator

Intravenous infusion of 1 mg levcromakalim followed by intravenous sumatriptan infusion.

干预措施: Levcromakalim (Drug)

placebo (isotonic saline)

Placebo Comparator

Intravenous infusion of placebo (isotonic saline) followed by intravenous sumatriptan infusion.

干预措施: Levcromakalim (Drug)

结局指标

主要结局

Dynamic diffusion weighted image (DWI)

时间窗: Before and after infusion of levcromakalim compared with before and after infusion of saline. Time of measurements is baseline, 20 minutes and 160 minutes after the infusion.

To measure transient diffusivity changes related to levcromakalim-induced CSD during the aura phase of migraine in subjects with migraine with aura.

次要结局

  • Vascular imaging after sumatriptan(Before and after infusion of sumatriptan. Time of measurements is 200 minutes and 210 minutes after the infusion.)
  • Vascular imaging before sumatriptan(Before and after infusion of levcromakalim compared with before and after infusion of saline. Time of measurements is baseline, 20 minutes and 160 minutes after the infusion.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohammad Al-Mahdi Al-Karagholi

Study investigator

Danish Headache Center

研究点 (1)

Loading locations...

相似试验